CS
VYNE icon

Credit Suisse’s VYNE Therapeutics VYNE Stock Holding History

Credit Suisse’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-136
Closed -$1K – 4328
2022
Q2 		$1K Buy
+136
New +$1.14K ﹤0.01% 3846
2021
Q1 		– Sell
-601
Closed -$69K – 4590
2020
Q4 		$69K Buy
601
+451
+301% +$56.7K ﹤0.01% 4215
2020
Q3 		$18K Sell
150
-50
-25% -$5.83K ﹤0.01% 3990
2020
Q2 		$25K Buy
+200
New +$27.1K ﹤0.01% 3911

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Credit Suisse's VYNE Position: Q3 2022 in Review

Credit Suisse sold out of VYNE Therapeutics (VYNE) in Q3 2022, closing a stake of 136 shares — an estimated $1K sold.

Credit Suisse first reported a position in VYNE in Q2 2020 and held it in 4 quarters. The position peaked at $69K in Q4 2020. 41 funds tracked by Wall St. Rank hold VYNE as of Q3 2022.

  • Credit Suisse reported no remaining VYNE Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 136 VYNE Therapeutics shares in Q3 2022, an estimated $1K.
  • Credit Suisse first reported a position in VYNE Therapeutics in Q2 2020 and held it in 4 quarters.
  • Credit Suisse's VYNE Therapeutics position peaked at $69K in Q4 2020.
  • 41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.